Clinical trial · Observational
The dıagnostıc Value of Serum autotaxın Level ın Colorectal Cancer
Serum autotaxın Level ın Colorectal Cancer
NCT06091592CI-TRIAL-00070622completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal cancer is one of the most common causes of cancer-related death. Early diagnosis is extremely important in terms of treatment and mortality. In this study, we investigated the diagnostic value of serum autotaxin levels in colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colo-rectal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Serum autotaxın levels | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patient ( cancer)
- description
- . The colorectal cancer patient group included clinical stage 1-3 patients of both sexes. Patients with metastatic disease, those who received neoadjuvant therapy, those who received systemic chemoradiotherapy, those who had any known systemic inflammatory or autoimmune disease, those with another concurrent malignancy, and those who had been previously diagnosed and treated for another malignancy were excluded from the study.
- interventionNames
- Other: Serum autotaxın levels
- label
- Control (healthy volunteer)
- description
- The control group included healthy volunteers who had undergone screening colonoscopy within the last month, had no pathology, had not been diagnosed with any malignant disease before, had no known systemic inflammatory or autoimmune disease, and had not been diagnosed with inflammatory bowel disease.
- interventionNames
- Other: Serum autotaxın levels
Primary outcomes (1)
- measure
- Serum autotaxın level
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * stage 1-3 colorectal cancer * control group included healthy volunteers who had undergone screening colonoscopy within the last month , had no pathology, Exclusion Criteria: * metastatic disease, * received neoadjuvant therapy * received systemic chemoradiotherapy * had any known systemic inflammatory or autoimmune disease * had a with another concurrent malignancy * had been previously diagnosed and treated for another malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.